Levothyroxine Sodium

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

27 Suppliers, 14 USDMF, 9 CEP/COS, 2 JDMF, 5 EU WC, 5 KDMF, 21 NDC API, 15 Listed Suppliers

DEVELOPMENTS

8 Drug(s) in Development

8 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

5 Suppliers

5 Suppliers

DOSSIERs // Finished Dosage Forms

533 Dossiers, 258 FDA Orange Book, 133 Europe, 29 Canada, 37 Australia, 23 South Africa, 53 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 0.0125MG;0.0031MG, TABLET;ORAL - 0.025MG;0.0063MG, TABLET;ORAL - 0.05MG;0.0125MG, TABLET;ORAL - 0.15MG;0.0375MG, TABLET;ORAL - 0.1MG;0.025MG, POWDER;INTRAVENOUS - 100MCG/VIAL, POWDER;INTRAVENOUS - 200MCG/VIAL, POWDER;INTRAVENOUS - 500MCG/VIAL, TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, TABLET;ORAL - 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, CAPSULE;ORAL - 0.013MG, CAPSULE;ORAL - 0.025MG, CAPSULE;ORAL - 0.0375MG, CAPSULE;ORAL - 0.044MG, CAPSULE;ORAL - 0.05MG, CAPSULE;ORAL - 0.0625MG, CAPSULE;ORAL - 0.075MG, CAPSULE;ORAL - 0.088MG, CAPSULE;ORAL - 0.112MG, CAPSULE;ORAL - 0.125MG, CAPSULE;ORAL - 0.137MG, CAPSULE;ORAL - 0.15MG, CAPSULE;ORAL - 0.175MG, CAPSULE;ORAL - 0.1MG, CAPSULE;ORAL - 0.2MG

RELATED EXCIPIENT COMPANIES

Suppliers, 31 Roquette, 31 Kerry, 20 SPI Pharma, 16 BASF, 15 Microlex e.U, 12 Gangwal Healthcare, 12 Sigachi Industries, 10 Corel Pharma Chem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 7 Gangwal Chemicals, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 7 Seppic, 6 Lonza Capsugel, 6 Actylis, 6 DFE Pharma, 5 Ideal Cures Pvt Ltd, 5 Vasa Pharmachem, 5 Ingredion Pharma Solutions, 4 Prachin Chemical, 4 ACG Worldwide, 4 DKSH, 3 Rochem International Inc, 3 Pharmatrans-Sanaq, 3 Kima Chemical, 2 Aeon Procare, 2 The Dow Chemical Company, 2 Nanjing Well Pharmaceutical, 2 Qualicaps, 2 Pfanstiehl, 1 Finar, 1 Jai Radhe Sales, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Ulanqab Kema New Material, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd

EXCIPIENTS BY APPLICATIONS

83 Fillers, Diluents & Binders, 44 Coating Systems & Additives, 40 Direct Compression, 31 Disintegrants & Superdisintegrants, 25 Granulation, 25 Taste Masking, 25 Controlled & Modified Release, 22 Thickeners and Stabilizers, 19 Lubricants & Glidants, 18 Chewable & Orodispersible Aids, 15 Parenteral, 14 Co-Processed Excipients, 14 Solubilizers, 9 Empty Capsules, 8 Film Formers & Plasticizers, 7 API Stability Enhancers, 4 Vegetarian Capsules, 4 Emulsifying Agents, 3 Topical, 3 Rheology Modifiers, 2 Coloring Agents

GLOBAL SALES INFORMATION

59 US Medicaid Prescriptions, 123 Finished Drug Prices

MARKET PLACE

30 APIs, 14 DOSSIERS // FDF

PATENTS

125 US Patents

125 US Patents

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods, 3 EDQM Standards, 3 USP Standards, 3 Other Ref. Standards

DIGITAL CONTENT

7 Data Compilation & Company Tracker #PharmaFlow, 82 News

List of Drug Master Files (KDMF) for Levothyroxine Sodium Active Pharmaceutical Ingredient (API) submitted to the Review Authority in Korea.